Latest Breaking News On - Peiqing qian - Page 1 : vimarsana.com

More than 80% of MS patients on Briumvi in the ULTIMATE trials had no signs of disease activity after the first six months, data show.

United statesSan diegoEnrique alvarezPeiqing qianSwedish neuroscience instituteUniversity of coloradoAmericas committee for treatmentResearch in multiple sclerosisAmericas committeeMultiple sclerosisDisease activity with ublituximabParticipants with relapsing multiple sclerosis